BioNexus Gene Lab Corp Common stock (BGLC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioNexus Gene Lab Corp Common stock (BGLC) has a cash flow conversion efficiency ratio of -0.181x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.23 Million) by net assets ($6.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BioNexus Gene Lab Corp Common stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
BioNexus Gene Lab Corp Common stock - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how BioNexus Gene Lab Corp Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioNexus Gene Lab Corp Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNexus Gene Lab Corp Common stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elecster Oyj A
HE:ELEAV
|
0.052x |
|
One SA
WAR:FMG
|
0.074x |
|
1CM INC.
F:IQ70
|
0.023x |
|
AS Latvijas Juras medicinas centrs
MU:UOM
|
-0.098x |
|
Eko Export SA
WAR:EEX
|
-0.017x |
|
Erika Carmel-Tech Ltd
TA:ERKA
|
0.155x |
|
Bhakti Agung Propertindo
JK:BAPI
|
-0.007x |
|
Robin Energy Ltd.
NASDAQ:RBNE
|
-0.037x |
Annual Cash Flow Conversion Efficiency for BioNexus Gene Lab Corp Common stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of BioNexus Gene Lab Corp Common stock from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see BioNexus Gene Lab Corp Common stock (BGLC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.32 Million | $-2.23 Million | -0.268x | -47.24% |
| 2023-12-31 | $9.66 Million | $-1.76 Million | -0.182x | -323.36% |
| 2022-12-31 | $6.67 Million | $544.03K | 0.082x | +6297.18% |
| 2021-12-31 | $7.18 Million | $9.16K | 0.001x | -98.46% |
| 2020-12-31 | $6.66 Million | $552.68K | 0.083x | +142.85% |
| 2019-12-31 | $1.12 Million | $-217.27K | -0.194x | -7.49% |
| 2018-12-31 | $1.52 Million | $-274.08K | -0.180x | -104.77% |
| 2017-12-31 | $94.63K | $357.22K | 3.775x | +492.70% |
| 2016-12-31 | $-1.31K | $-835.00 | 0.637x | -- |
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more